Computer-Aided Structure-Based Design of Multitarget Leads for Alzheimer’s Disease
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/16986
Ficheiros no ítem
Metadatos do ítem
Título: | Computer-Aided Structure-Based Design of Multitarget Leads for Alzheimer’s Disease |
Autor/a: | Domínguez, José L. Fernández-Nieto, Fernando Castro, Marian CATTO, Marco Paleo, M. Rita Porto, Silvia Sardina, F. Javier Brea Floriani, José Manuel Carotti, Angelo Villaverde Cameron-Walker, María del Carmen Sussman, Fredy Salomon |
Centro/Departamento: | Universidade de Santiago de Compostela. Centro de Investigación en Química Biolóxica e Materiais Moleculares Universidade de Santiago de Compostela. Departamento de Química Orgánica |
Data: | 2015 |
Editor: | American Chemical Society |
Cita bibliográfica: | Domínguez, J., Fernández-Nieto, F., Castro, M., Catto, M., Paleo, M., & Porto, S. et al. (2015). Computer-Aided Structure-Based Design of Multitarget Leads for Alzheimer’s Disease. J. Chem. Inf. Model., 55(1), 135-148. doi: 10.1021/ci500555g |
Resumo: | Alzheimer’s disease is a neurodegenerative pathology with unmet clinical needs. A highly desirable approach to this syndrome would be to find a single lead that could bind to some or all of the selected biomolecules that participate in the amyloid cascade, the most accepted route for Alzheimer disease genesis. In order to circumvent the challenge posed by the sizable differences in the binding sites of the molecular targets, we propose a computer-assisted protocol based on a pharmacophore and a set of required interactions with the targets that allows for the automated screening of candidates. We used a combination of docking and molecular dynamics protocols in order to discard nonbinders, optimize the best candidates, and provide a rationale for their potential as inhibitors. To provide a proof of concept, we proceeded to screen the literature and databases, a task that allowed us to identify a set of carbazole-containing compounds that initially showed affinity only for the cholinergic targets in our experimental assays. Two cycles of design based on our protocol led to a new set of analogues that were synthesized and assayed. The assay results revealed that the designed inhibitors had improved affinities for BACE-1 by more than 3 orders of magnitude and also displayed amyloid aggregation inhibition and affinity for AChE and BuChE, a result that led us to a group of multitarget amyloid cascade inhibitors that also could have a positive effect at the cholinergic level |
Versión do editor: | https://doi.org/10.1021/ci500555g |
URI: | http://hdl.handle.net/10347/16986 |
DOI: | 10.1021/ci500555g |
ISSN: | 1549-9596 |
E-ISSN: | 1549-960X |
Dereitos: | © 2015 American Chemical Society |
Coleccións
-
- CIQUS-Artigos [477]
- QO-Artigos [438]